文献速递临床试验与 GCP流行病学与生物统计

生活方式与危险因素干预对外周动脉疾病结局的影响:标准医疗与结构化方案的随机对照试验协议

The effect of lifestyle and risk factor modification on occlusive peripheral arterial disease outcomes: standard healthcare vs structured programme-for a randomised controlled trial protocol.
PubMed 文献 · Trials · 2021-02-13

外周动脉疾病(PAD)全球影响超过2亿人,是心血管事件的标志。本研究为随机平行组主动对照试验,在三级血管中心比较结构化危险因素干预方案与标准医疗在PAD患者中达成治疗目标的效果,主要结局为3个月和12个月时危险因素治疗达标情况。

要点

  • PAD患者心血管死亡相对风险与冠心病或脑血管病患者相当,但接受危险因素治疗的比例更低。
  • 试验主要评价结构化生活方式与危险因素干预方案在3个月和12个月时达成PAD危险因素治疗目标的效果。
  • 次要结局包括12个月时无截肢生存、临床改善、血流动力学改善、血运重建需求等。

核心结论

  • 该试验旨在通过高质量、有足够把握度的临床试验,明确结构化生活方式与危险因素干预方案在PAD危险因素治疗达标中的有效性。

研究设计与样本

  • 随机、平行组、主动对照试验,在三级血管中心比较危险因素干预方案与标准医疗。
  • 研究对象为外周动脉疾病患者,主要结局为3个月和12个月时PAD危险因素治疗达标情况。

关键数值与推荐

  • 主要结局:3个月和12个月时PAD危险因素治疗达标情况。
  • 次要结局:12个月时无截肢生存、临床改善、血流动力学改善、血运重建需求、血运重建结局、生活质量变化及不良事件发生率。
  • 试验注册:EudraCT 2017-002964-41(2017年7月11日)和ClinicalTrials.gov NCT03935776(2019年5月2日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral arterial disease (PAD) affects more than 200 million of the global population. PAD represents a marker for premature cardiovascular events. Patients with PAD, even in the absence of a history of myocardial infarction or ischemic stroke, have approximately the same relative risk of death from cardiovascular causes as patients with a history of coronary or cerebrovascular disease. Despite the high prevalence of PAD and the strong association with cardiovascular morbidity and mortality, patients with PAD are less likely to receive appropriate treatment for their atherosclerotic risk factors than those who are being treated for coronary artery disease. Atherosclerotic risk factor identification and modification play an important role in reducing the number of adverse outcomes among patients with atherosclerosis. Risk reduction therapy decreases the risk of cardiovascular mortality and morbidity in patients with PAD. In this study, we aim to evaluate the effectiveness of a lifestyle and risk factor modification intervention programme in achieving treatment goals for PAD risk factors. METHODS: This is a randomised, parallel group, active-control trial to compare the effectiveness of the risk factor modification intervention programme to standard healthcare in a tertiary vascular care centre, in the reduction of modified risk factors in PAD patients. The primary outcome of this study is to evaluate the effectiveness of a lifestyle and risk factor modification intervention programme in achieving treatment goals for PAD risk factors at 3 and 12 months. The secondary outcomes are to compare the impact of the programme on clinical outcomes in PAD patients at 12 months. Secondary outcomes include amputation-free survival, clinical improvement, haemodynamic improvement, need for revascularisation procedures, outcomes of revascularisation procedures, changes in quality of life and the incidence of adverse events. DISCUSSION: This study will provide clear evidence on the effectiveness of a lifestyle and risk factor modification intervention programme in achieving treatment goals for PAD risk factors, through a high-quality, well-powered clinical trial. TRIAL REGISTRATION: This trial was registered (11/07/2017) on the European Clinical Trials Database (EudraCT number 2017-002964-41) and ClinicalTrials.gov ( NCT03935776 ) which was registered on 02 May 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Elfghi M, Jordan F, Dunne D, et al. The effect of lifestyle and risk factor modification on occlusive peripheral arterial disease outcomes: standard healthcare vs structured programme-for a randomised controlled trial protocol. Trials. 2021. PMID: 33581715. doi:10.1186/s13063-021-05087-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。